Oncolytics Biotech Inc.
ONCYHealthcare|Biotechnology|US
$0.44
-0.01 (-2.09%)
DCF Value
$0.02
Cash / Share
$0.03
Financials
Financial Snapshot
Market Cap
$44.1M
Enterprise Value
$58.6M
Revenue (TTM)
$0.00
Net Income (TTM)
-$38.2M
Cash & Investments
$4.1M
Net Cash
$3.7M
Free Cash Flow (TTM)
-$28.9M
Operating CF (TTM)
-$28.9M
Debt/Equity
-0.07
Cash Runway & Burn Rate
Cash on Hand
$4.1M
Quarterly Burn
$7.2M
Monthly Burn
$2.4M
Est. Runway
~0.6 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $14.1M | $11.8M | $13.7M | $14.1M | $31.2M | $41.3M | $32.1M | $34.9M | $15.9M | $7.1M | $4.1M | |
| Operating Cash Flow | -$12.5M | -$14.9M | -$11.9M | -$19.9M | -$22.1M | -$22.4M | -$17.2M | -$21.4M | -$19.9M | -$20.1M | -$28.9M | |
| Free Cash Flow | -$12.5M | -$15.0M | -$12.0M | -$19.9M | -$22.1M | -$22.7M | -$17.2M | -$21.5M | -$20.1M | -$20.1M | -$28.9M | |
| Capital Expenditure | -$23.5K | -$105.8K | -$107.5K | -$10.9K | -$29.0K | -$286.0K | -$40.5K | -$6.0K | -$174.0K | -$6.0K | -$12.6K | |
| Financing Cash Flow | $956.1K | $12.8M | $13.3M | $21.0M | $39.8M | $33.0M | $9.0M | $24.1M | $5.0M | $14.1M | $22.2M |
R&D Spending
R&D (TTM)
$17.2M
R&D Intensity
—
R&D Growth vs Prior
+29.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $9.8M | $9.4M | $9.4M | $10.8M | $12.9M | $12.9M | $11.4M | $13.3M | $15.4M | $13.3M | $17.2M | |
| SG&A | $5.4M | $6.2M | $7.2M | $9.3M | $12.5M | $12.9M | $8.2M | $11.8M | $10.1M | $15.4M | $21.2M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $162.2K | $90.8K | $95.4K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | -$162.2K | -$90.8K | -$95.4K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $9.8M | $9.4M | $9.4M | $10.8M | $12.9M | $12.9M | $11.4M | $13.3M | $15.4M | $13.3M | $17.2M | |
| SG&A | $5.4M | $6.2M | $7.2M | $9.3M | $12.5M | $12.9M | $8.2M | $11.8M | $10.1M | $15.4M | $21.2M | |
| Operating Income | -$15.3M | -$15.6M | -$16.7M | -$20.1M | -$25.5M | -$26.2M | -$19.8M | -$25.5M | -$25.5M | -$28.7M | -$38.3M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$15.1M | -$15.5M | -$16.5M | -$33.1M | -$22.5M | -$26.3M | -$18.2M | -$20.8M | -$22.7M | -$28.7M | -$38.1M | |
| Net Income | -$15.1M | -$15.6M | -$17.0M | -$45.6M | -$22.5M | -$26.3M | -$18.3M | -$20.9M | -$22.8M | -$28.8M | -$38.2M | |
| EPS (Diluted) | -1.20 | -1.12 | -1.06 | -1.50 | -0.48 | -0.49 | -0.44 | -0.41 | -0.30 | -0.41 | -0.34 | |
| EBITDA | -$13.8M | -$14.7M | -$17.2M | -$19.7M | -$25.0M | -$25.8M | -$19.5M | -$25.2M | -$25.5M | -$28.7M | -$38.0M | |
| Shares Out. (M) | 12.62 | 13.94 | 16.02 | 22.14 | 40.34 | 53.51 | 58.03 | 67.62 | 76.48 | 95.86 | 119.74 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.0M | $11.8M | $13.7M | $14.1M | $31.2M | $41.3M | $11.7M | $34.9M | $15.9M | $7.1M | $4.1M | |
| Short-Term Investments | $2.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $20.5M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $14.4M | $17.8M | $14.5M | $18.9M | $33.7M | $44.9M | $35.7M | $38.2M | $18.9M | $9.4M | $7.1M | |
| Total Assets | $14.8M | $18.2M | $14.9M | $19.7M | $34.3M | $45.9M | $37.3M | $38.8M | $20.2M | $10.4M | $7.7M | |
| Total Current Liabilities | $4.1M | $5.2M | $2.8M | $12.9M | $2.7M | $2.7M | $3.9M | $4.2M | $6.7M | $8.4M | $5.2M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $4.1M | $9.9M | $8.7M | $19.8M | $9.6M | $9.8M | $10.8M | $11.3M | $14.2M | $15.6M | $13.8M | |
| Stockholders' Equity | $10.7M | $8.3M | $6.2M | -$107.9K | $24.8M | $36.1M | $26.5M | $27.6M | $6.0M | -$5.2M | -$6.2M | |
| Retained Earnings | -$278.8M | -$294.4M | -$311.5M | -$344.6M | -$367.1M | -$393.4M | -$418.3M | -$446.0M | -$477.7M | -$589.3M | -$448.2M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.5M | -$14.9M | -$11.9M | -$19.9M | -$22.1M | -$22.4M | -$17.2M | -$21.4M | -$19.9M | -$20.1M | -$28.9M | |
| Capital Expenditure | -$23.5K | -$105.8K | -$107.5K | -$10.9K | -$29.0K | -$286.0K | -$40.5K | -$6.0K | -$174.0K | -$6.0K | -$12.6K | |
| Free Cash Flow | -$12.5M | -$15.0M | -$12.0M | -$19.9M | -$22.1M | -$22.7M | -$17.2M | -$21.5M | -$20.1M | -$20.1M | -$28.9M | |
| Investing Cash Flow | -$51.4K | $2.0M | -$107.5K | -$10.9K | -$29.0K | -$286.0K | -$15.0M | $15.2M | -$174.0K | -$6.0K | -$12.3K | |
| Financing Cash Flow | $956.1K | $12.8M | $13.3M | $21.0M | $39.8M | $33.0M | $9.0M | $24.1M | $5.0M | $14.1M | $22.2M | |
| Issuance of Stock | $956.1K | $12.5M | $13.2M | $18.0M | $38.3M | $33.4M | $9.3M | $24.4M | $5.0M | $14.1M | $20.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$447.5K | -$461.0K | -$366.0K | -$280.7K | -$306.8K | -$242.5K | $0.00 | -$70.1K | |
| Stock Based Comp. | $406.1K | $578.7K | $1.4M | $1.5M | $2.6M | $3.8M | $1.8M | $1.6M | $2.0M | $3.1M | $4.1M | |
| Net Change in Cash | -$12.0M | -$198.2K | $1.9M | $448.1K | $17.1M | $10.0M | -$21.8M | $17.5M | -$15.3M | -$5.9M | -$8.7M |
Dilution Tracker
Shares outstanding grew 137.6% over 5 years — significant dilution
Shares Outstanding
100M
5-Year Share Growth
+137.6%
Stock Issuance (TTM)
$20.1M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 12.62 | 13.94 | 16.02 | 22.14 | 40.34 | 53.51 | 58.03 | 67.62 | 76.48 | 95.86 | 119.74 | |
| Change vs Prior % | — | 10.4% | 14.9% | 38.2% | 82.2% | 32.7% | 8.4% | 16.5% | 13.1% | 25.3% | 24.9% | |
| Stock Issuance | $956.1K | $12.5M | $13.2M | $18.0M | $38.3M | $33.4M | $9.3M | $24.4M | $5.0M | $14.1M | $20.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $406.1K | $578.7K | $1.4M | $1.5M | $2.6M | $3.8M | $1.8M | $1.6M | $2.0M | $3.1M | $4.1M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -141.6% | -188.5% | -275.0% | 42219.6% | -90.9% | -72.9% | -69.0% | -75.9% | -381.0% | 551.7% | 1020.2% | |
| ROA % | -102.6% | -86.0% | -114.6% | -231.7% | -65.5% | -57.3% | -49.0% | -53.9% | -112.9% | -276.4% | -498.1% | |
| ROIC % | -143.1% | -120.8% | -138.3% | -282.6% | -79.8% | -60.3% | -59.0% | -73.4% | -185.4% | -1250.6% | -1480.5% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 10.1% | 44.1% | -5.1% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -9.9% | -2.0% | -6.8% | -20.9% | -26.4% | -3.0% | 24.4% | -28.4% | -0.3% | -12.5% | |
| Net Income | -10.3% | -3.1% | -9.1% | -167.4% | 50.6% | -16.9% | 30.4% | -14.3% | -9.0% | -26.2% | |
| EPS (Diluted) | -3.4% | 6.7% | 5.4% | -41.5% | 68.0% | -2.1% | 10.2% | 6.8% | 26.8% | -36.7% | |
| Operating Cash Flow | 17.0% | -19.3% | 20.0% | -67.0% | -10.9% | -1.7% | 23.3% | -24.6% | 7.3% | -1.2% | |
| Free Cash Flow | 17.4% | -20.0% | 19.8% | -65.6% | -10.9% | -2.8% | 24.1% | -24.4% | 6.5% | -0.3% | |
| R&D Expense | 13.6% | -3.9% | 0.3% | 14.9% | 19.7% | -0.2% | -12.0% | 17.4% | 15.7% | -13.8% | |
| SG&A Expense | 4.4% | 15.9% | 16.6% | 28.7% | 34.2% | 2.8% | -36.4% | 44.5% | -14.6% | 52.6% | |
| Total Assets | -46.1% | 23.0% | -18.1% | 32.2% | 74.7% | 33.6% | -18.6% | 4.0% | -48.0% | -48.5% | |
| Book Value / Share | -59.3% | -29.8% | -34.9% | -101.3% | 12690.6% | 9.9% | -32.3% | -10.8% | -80.8% | -169.5% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -20.6% | 62.9% | -43.1% | 13.4% | 151.5% | -27.4% | |
| Diluted Shares | 6.5% | 10.4% | 14.9% | 38.2% | 82.2% | 32.7% | 8.4% | 16.5% | 13.1% | 25.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B-12.04
10Y Low / Med / High2.60 / 4.95 / 16.80
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.02
Cash / Share
$0.03
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -2.24 | -6.09 | -2.33 | -4.12 | -6.32 | -3.59 | -5.02 | -4.36 | -4.38 | -2.92 | -1.80 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 3.17 | 11.47 | 6.39 | -1267.26 | 4.95 | 2.60 | 4.83 | 4.39 | 16.80 | -22.05 | -12.04 | |
| EV/EBITDA | -1.58 | -5.65 | -1.51 | -6.26 | -3.66 | -2.07 | -5.97 | -3.43 | -3.36 | -3.79 | -1.54 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-95.25
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $1.2M | $594.6K | $17.1M |
| Net Income | -$33.1M | -$27.0M | -$26.7M |
| EPS | $-0.36 | $-0.28 | $-0.27 |
| # Analysts (EPS) | 2 | 3 | 4 |